& Biologics

Intellectual property is of paramount importance in the pharmaceutical sector. While some degree of regulatory protection is available in many markets, patents (and their PTE/SPC extensions) will often provide a considerable commercial & exclusivity uplift for a given asset. With such high value at stake, pharmaceutical patents can often become the target of determined and creative litigation – so insightful and careful drafting and prosecution is particularly important in this area.

Our large team of pharmaceutical IP specialists means that we can offer genuine expertise across all classes of therapeutics, from small molecule drugs and modulators, antibody-drug conjugates and other bifunctional molecules such as PROTACS, to biologics and cell therapeutics including polypeptides, monoclonal antibodies, nucleic acid therapeutics, vaccines, stem cells and cellular immunotherapy.

We know how to support drug development from conception to marketing and have done so for numerous biologics, including Lyxumia® and Nutropin®, for antibody-drug conjugates including Zynlonta®, and for small molecules including a blockbuster anti-cancer drug. As further examples of our work with high-value therapeutics, we have developed and protected the patent portfolios for monoclonal antibodies including Herceptin®, Humira®, Avastin®, Rituxan®, Lucentis®, Xolair® and Perjeta®.

Our attorneys also have expertise in obtaining broad IP protection for novel and emerging classes of therapeutics. For instance, we obtained the first class-level patent protection for aptamers and have since prosecuted over 150 patents related to aptamer technology.

Of course, pharmaceutical IP support can extend long after initial global launch. We recognise the importance patent portfolio building and life-cycle management, and we can support the drafting and prosecution of patents protecting follow-on innovations such as novel methods of synthesis, novel salts and polymorphs, high purity forms, pharmaceutical formulations, combination therapies, dosage regimes and new medical uses.

Our patent attorneys are supported by our specialist Extensions and Exclusivity team made up of experts having many years of experience in SPCs, PTEs and Regulatory Exclusivity, including an experienced IP counsel who previously specialised in this area at a global pharmaceutical company. The team regularly supports clients on strategic commercial exclusivity analysis for their products – taking account of the patent, regulatory and real-world factors in order to guide extensions strategy, before progressing on to the SPC and PTE filings themselves.

Experts in Pharma & Biologics innovations


NCEs & Synthetic Methods


Follow-on Pharma Innovation


Antibodies & ADCs


Cell Therapy


Nucleic Acid Therapeutics


Protein Therapeutics


Term Extensions & Data Exclusivity

Meet our specialists

SPC Report Mock-Up v2-compressed

Special Report

Pharma and Life Sciences Patent Extensions in Europe

Having compiled and analysed real-world data, this Special Report sets out to provide valuable insights into the following questions that may face decision-makers handling SPC protection for a new drug:

  1. What do the headline SPC statistics tell us?
  2. How to approach the decision of which patent to extend?
  3. What forms of medical technology are being protected by SPCs?
  4. What SPC periods are typically obtained?
  5. How do SPC periods vary with technology type?
  6. How do SPC periods overlay with regulatory protection?
  7. What commercial value can arise from SPCs?

Read our latest blogs

FDA decision on MDMA therapy hangs in the balance

FDA decision on MDMA therapy hangs in the balance

by Joseph Newcombe

Recent positive data from a phase III clinical trial of MDMA assisted psychotherapy for the treatment of post-traumatic stress disorder has fuelled excitement around Lykos Therapeutics’ bid to become ...

The brilliant dawn of AI drug discovery

The brilliant dawn of AI drug discovery

by Camille Terfve

Computer simulations are solving challenges previously thought uncrackable.

Updates to the Guidelines for Examination at the EPO

Updates to the Guidelines for Examination at the EPO

by Rebecca Brooks

The Guidelines for Examination at the EPO (which will be referred to as “the Guidelines” in this article) elaborate on the various articles/rules of the European Patent Convention and provide ...

We work at every stage of the IP lifecycle


Drafting, Filing & Prosecution
Portfolio Management
Searching & Watching
Renewals & EP Validations


Pre-action Advice
Oppositions & Appeals
Alternative Dispute Resolution


Strategic Advice
Commercial Issues
Corporate Support

Forward Magazines Overlapping 8

Mewburn Ellis


Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.